Amperometric biosensors for detection of the prostate cancer marker (PSA).

Prostate specific antigen (PSA) has been identified as the most reliable clinical tool for diagnosing and monitoring prostate cancer (CAP). Since, there is no curative therapy available for prostate cancer, detecting the disease at the early stage is the best hope of increasing mortality rate. There are some procedures available for the detection of prostate cancer e.g. Tandem-R PSA, Hybritech Inc. (USA), IMx-PSA Abbott Laboratories (USA). However, these are time consuming and costly. We have developed a very simple and cost effective technique for identification and monitoring of prostate cancer using amperometric immunosensor. PSA is a glycoprotein with 93% peptide and 7% sugar content and isoelectric pH of 6.9. It may exist in the human serum as free (f-PSA) and complex (PSA-ACT) forms. Normally if the total PSA (t-PSA) level is more than 10 ng/ml, CAP is suspected. This paper presents an amperometric detection procedure for t-PSA using three electrode system in which working electrode (WE) is made of hydroxyethyl cellulose (HEC) and rhodinised carbon. The method used is rapid, very easy to use and involves low cost compared with other procedures. The electrochemical response was directly observed due to enzymatic reaction via a sandwich immunoassay on the WE. Monoclonal capture antibody (Mab) to PSA was immobilised on the WE and the other Mab labelled by the enzyme marker, horseradish peroxidase (HRP), was used as a tracer antibody.

[1]  E. Diamandis,et al.  Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. , 1996, Clinical chemistry.

[2]  Y. Xu,et al.  Electrochemical enzyme immunoassay for serum prostate-specific antigen at low concentrations. , 1997, Clinical chemistry.

[3]  P. O’Neill,et al.  A comparison of three fluorophores for use in an optical biosensor for the measurement of prostate-specific antigen in whole blood , 1995 .

[4]  G. Murphy,et al.  Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. , 1980, Cancer research.

[5]  A P Turner,et al.  Screen-printed amperometric biosensors for the rapid measurement of L- and D-amino acids. , 1999, The Analyst.

[6]  W. J. Allard,et al.  Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. , 1998, Clinical chemistry.

[7]  B. G. Blijenberg,et al.  Some Analytical Considerations on the Measurement of Prostate-Specific Antigen , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[8]  W G Bardsley,et al.  The steady-state kinetics of peroxidase with 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulphonic acid) as chromogen. , 1975, The Biochemical journal.

[9]  J Rishpon,et al.  A one-step, separation-free amperometric enzyme immunosensor. , 1996, Biosensors & bioelectronics.

[10]  S. Fosså,et al.  Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. , 1998, The Journal of urology.

[11]  Sandra K. Wegner,et al.  Characterization of 10 new monoclonal antibodies against prostate‐specific antigen by analysis of affinity, specificity and function in sandwich assays , 1997, International journal of cancer.

[12]  Alexander M. Yacynych,et al.  Use of polymer films in amperometric biosensors , 1995 .

[13]  T. M. Chu,et al.  Prostate‐specific antigen in screening of prostate cancer , 1994, Journal of clinical laboratory analysis.

[14]  E. Schmidt,et al.  The effect of n-3 fatty acids on neutrophil chemiluminescence. , 1995, Scandinavian journal of clinical and laboratory investigation.

[15]  James T. Wu,et al.  Development of an immunoassay specific for the PSA‐ACT complex without the problem of high background , 1998, Journal of clinical laboratory analysis.

[16]  K. Yeung,et al.  Equivalent recognition of free and act‐complexed PSA in a monoclonal‐polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody , 1998, Journal of clinical laboratory analysis.

[17]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[18]  G. Klee,et al.  Development of a highly sensitiveimmunochemiluminometric assay for prostate-specific antigen , 1994 .

[19]  H. Lilja Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. , 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[20]  M. Stearns,et al.  Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. , 1996, Oncology research.

[21]  S. Madersbacher,et al.  Validation of a 10-minute dipstick test for serum prostate-specific antigen. , 1996, European urology.

[22]  P. Sarkar,et al.  One-step separation-free amperometric biosensor for the detection of protein , 2000 .